Hoshimoto et al. (37) have demonstrated that immune checkpoint inhibitors may improve the prognosis of small bowel adenocarcinoma patients with low FoxP3/CD8 ratio and PD-L2 expression. This evidence concerns the gene PDCD1LG2 and small intestine adenocarcinoma.